drugset / Trial / NCT02544607
Ketamine for Depression: An MRI Study
Phase 4
Completed
25 enrolled
Massachusetts General Hospital
Brain & Behavior Research Foundation · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelOther
Summary
Ketamine has been shown to decrease symptoms of anxious depression quickly. This decrease has been shown to last for up to one month. MRI technology will be used before and after ketamine for patients with depression to examine the extent to which certain brain areas predict ketamine's antidepressant effects.
Timeline
- Start
- 2016-03
- Primary completion
- 2017-12-29
- Completion
- 2017-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 0.5 mg/kg | Intravenous |